药品和生物技术的选择权和评估交易（2016-2024）

本报告深入了解和分析公司如何以及为何进行选择权和评估交易。

本报告提供了2016年至2024年选择权和评估交易的详细资讯。

此报告提供了各方之间宣布的选择权/评估交易的付款条款。这些资料提供了有关支付条款和其他交易条款的宝贵见解。

了解潜在合作伙伴谈判条款的弹性，并深入了解谈判过程，以了解条款谈判期间的预期结果。许多小型企业会要求提供付款条件的详细信息，但在包括付款方式和权利如何转让时，细节是关键。

本报告提供了自2016年以来宣布的期权/评估交易的完整列表，目前协议案件/合作伙伴资料库中记录的内容，并包括可用的财务条款，以及公司及其合作伙伴向证券交易委员会提交的实际许可协议文件的线上副本的连结。

主要优点

本报告为读者提供了以下主要好处：

• 了解2016年以来的交易完成趋势
• 查看选择权和评估交易
• 基准分析：确定交易的市场价值
• 财务状况
• 交易清单：依公司名称（A-Z）、依治疗领域、依技术类型
• 主要交易（金额基础）
• 最活跃的交易者
• 每笔交易的资产识别和交易条件
• 取得合约文件：深入了解交易结构
• 实质审查：评估拟议交易条款对合作伙伴公司的适用性
• 节省数百小时的研究时间

调查范围

• 本报告目的是详细了解世界领先的生物製药公司的选择权/估值趋势和交易结构。

此报告包含以下资讯：

• 生物製药产业选择权和评估交易的趋势
• 选择权/评估交易架构：概述
• 製药和生技产业的选择权和评估交易记录列表
• 主要选择权和评估交易（金额基础）
• 最活跃的选择权和评估交易者
• 用于选项和评估的主要合作伙伴资源

此报告列出了可获得资讯的交易：

• 依公司名称（A-Z）
• 依交易金额
• 依治疗领域
• 依技术类型
• 每个交易标题都透过网路连结连结到实际交易记录的线上版本。
• 此报告提供了对选择权和评估合约的可用合约文件的全面存取。

透过分析合约协议，实质审查可以：

• 授予和选择了哪些权利？
• 合约授予了哪些权利？
• 授予哪些专有权？
• 合约的付款结构是怎样的？
• 如何审核销售和付款？
• 合约期限是多久？
• 合约的主要条款是如何定义的？
• 如何对待和拥有知识产权？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 如何管理保密和发布？
• 如何解决争议？
• 什么情况下可以取消合约？
• 如果所有者发生变化会怎样？
• 已商定何种类型的分授权或分包条款？
• 公司需要哪些样板条款？
• 哪些样板条款会根据合作伙伴和交易类型的不同而有所不同？
• 每家公司都主张合约法中的哪一个管辖权？

目录

执行摘要

第1章 简介

第2章 选项与评估趋势

• 简介
• 定义选择权和评估交易
• 选择权和评估交易的趋势（自2016年以来）
  • 选择权/评估交易：依年份（2016-2024年）
  • 选择权/评量交易：依开发阶段（2016-2024年）
  • 选择权/评估交易：依产业（2016-2024年）
  • 选择权/评估交易：依治疗领域（2016-2024年）
  • 选择权/评估交易：依技术类型（2016-2024年）
  • 选择权/评估交易：针对最活跃的公司（2016-2024年）
• 签订选择权/评估合约的原因
• 未来选择权与评估交易

第3章 选择权与评估交易结构概述

• 简介
• 选项/评估结构

第4章 主要选择权及评估交易

• 简介
• 主要选择权和评估交易（金额基础）

第5章 25 位最活跃的选择权和评估交易商

• 简介
• 前 25 位最活跃的选择权和评估交易商（进行交易的公司）

第6章 选择权和评估交易清单（包括合约细节）

• 简介
• 选择权与评估交易合约（2016-2024年）
• 交易列表
• 交易清单：选择权/评估交易，依公司名称（A-Z）
• 交易清单：选择权/评估交易，依治疗领域
• 交易清单：选择权/评估交易，依技术类型

关于Wildwood Ventures

• 目前的合作关係
• 当前合约
• Current Partnering 发布的最新报告标题

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter option and evaluation deals.

Fully revised and updated, the report provides details of option and evaluation deals from 2016 to 2024.

The report provides access to option and evaluation deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of option and evaluation deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in option and evaluation as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of option and evaluation deals.

Chapter 4 provides a review of the leading option and evaluation deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active option and evaluation dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of option and evaluation deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the option and evaluation deal.

The deal directory includes a comprehensive listing of all option and evaluation deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in option and evaluation dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about option and evaluation alliances.

Key benefits

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse option and evaluation deals
• Benchmark analysis - identify market value of transactions
• Financials terms
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Option and Evaluation Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the option and evaluation trends and structure of deals entered into by leading biopharma companies worldwide.

Option and Evaluation Deals in Pharmaceuticals and Biotechnology includes:

• Trends in option and evaluation dealmaking in the biopharma industry
• Overview of option and evaluation deal structure
• Directory of option and evaluation deal records covering pharmaceutical and biotechnology
• The leading option and evaluation deals by value
• Most active option and evaluation dealmakers
• The leading option and evaluation partnering resources

In Option and Evaluation Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for option and evaluation deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in option and evaluation dealmaking

• 2.1. Introduction
• 2.2. Definition of option and evaluation deal
• 2.3. Trends in option and evaluation deals since 2016
  • 2.3.1. Option and evaluation dealmaking by year, 2016-2024
  • 2.3.2. Option and evaluation dealmaking by phase of development, 2016-2024
  • 2.3.3. Option and evaluation dealmaking by industry sector, 2016-2024
  • 2.3.4. Option and evaluation dealmaking by therapy area, 2016-2024
  • 2.3.5. Option and evaluation dealmaking by technology type, 2016-2024
  • 2.3.6. Option and evaluation dealmaking by most active company, 2016-2024
• 2.4. Reasons for entering into option and evaluation partnering deals
• 2.5. The future of option and evaluation deals

Chapter 3 - Overview of option and evaluation deal structure

• 3.1. Introduction
• 3.2. Option and evaluation agreement structure

Chapter 4 - Leading option and evaluation deals

• 4.1. Introduction
• 4.2. Top option and evaluation deals by value

Chapter 5 - Top 25 most active option and evaluation dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active option and evaluation dealmakers

Chapter 6 - option and evaluation deals including contracts directory

• 6.1. Introduction
• 6.2. Option and evaluation deals with contracts 2016-2024
• Deal directory
• Deal directory - option and evaluation dealmaking by companies A-Z
• Deal directory - option and evaluation dealmaking by therapy area
• Deal directory - option and evaluation dealmaking by technology type

About Wildwood Ventures

• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of option and evaluation
• Figure 2: Trends in option and evaluation deal announcements, 2016-2024
• Figure 3: Option and evaluation deals signed at each phase of development, 2016-2024
• Figure 4: Option and evaluation deals by industry sector, 2016-2024
• Figure 5: Option and evaluation deals by therapy area, 2016-2024
• Figure 6: Option and evaluation deals by technology type, 2016-2024
• Figure 7: Top 25 most active option and evaluation dealmakers, 2016-2024
• Figure 8: Top option and evaluation deals by value, 2016-2024
• Figure 9: Most active option and evaluation dealmakers, 2016-2024